This one-pager provides an overview of the FDA accelerated approval pathway, including how surrogate endpoints are used to help patients access promising therapies earlier. It also explains why accelerated approval is especially important for rare diseases with significant unmet medical need.
New Name, Same Commitment to Rare Diseases
The EveryLife Foundation for Rare Diseases has become The RARE Foundation! Read more about our new brand and how it unifies our advocacy work on behalf of the rare disease community.
